Genetic variation inIL-1β, IL-2, IL-6, TSPOandBDNFand response to duloxetine or placebo treatment in major depressive disorder Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • AIM: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. PATIENTS & METHODS: Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale. RESULTS: IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing. CONCLUSION: Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.

authors

  • Maciukiewicz, Malgorzata
  • Marshe, Victoria S
  • Tiwari, Arun K
  • Fonseka, Trehani M
  • Freeman, Natalie
  • Rotzinger, Susan
  • Foster, Jane
  • Kennedy, James L
  • Kennedy, Sidney H
  • Müller, Daniel J

publication date

  • November 2015

has subject area